WHAT IS CLAIMED IS:

1. A compound of formula I



I

or a pharmaceutically acceptable salt, crystal form, or hydrate, wherein:

A is

a) an aryl ring, wherein any stable aryl ring atom is independently unsubstituted or substituted with

1) halogen,

2) NO_2,

3) CN,

4) $CR^{46}=C(R^{47}R^{48})_2$,

5) $C\equiv C\ R^{46}$,

6) $(CR^iR^j)_rOR^{46}$,

7) $(CR^iR^j)_rN(R^{46}R^{47})$,

8) $(CR^iR^j)_r\ C(O)R^{46}$,

9) $(CR^iR^j)_r\ C(O)OR^{46}$,

10) $(CR^iR^j)_rR^{46}$,

11) $(CR^iR^j)_r\ S(O)_{0-2}R^{61}$,

12) $(CR^iR^j)_r\ S(O)_{0-2}N(R^{46}R^{47})$,

13) $OS(O)_{0-2}R^{61}$,

14) $N(R^{46})C(O)R^{47}$,

15) $N(R^{46})S(O)_{0-2}R^{61}$,

16) $(CR^iR^j)_rN(R^{46})R^{61}$,

17) $(CR^iR^j)_rN(R^{46})R^{61}OR^{47}$,

18) $(CR^iR^j)_rN(R^{46})(CR^kR^l)_sC(O)N(R^{47}R^{48})$,

19) $N(R^{46})(CR^iR^j)_rR^{61}$,

20) $N(R^{46})(CR^iR^j)_rN(R^{47}R^{48})$,

21) $(CR^iR^j)_rC(O)N(R^{47}R^{48})$,

22) oxo,

b) a heteroaryl ring selected from the group consisting of

a 5-membered unsaturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting or N, O or S,

a 6-membered unsaturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting N, O and S, and

a 9- or 10-membered unsaturated bicyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting or N, O or S,

wherein any stable S heteroaryl ring atom is unsubstituted or mono- or di-substituted with oxo, and any stable C or N heteroaryl ring atom is independently unsubstituted or substituted with

1) halogen,
2) NO_2,
3) CN,
4) $CR^{46}=C(R^{47}R^{48})_2$,
5) $C\equiv C\,R^{46}$,
6) $(CR^iR^j)_rOR^{46}$,
7) $(CR^iR^j)_rN(R^{46}R^{47})$,
8) $(CR^iR^j)_r\,C(O)R^{46}$,
9) $(CR^iR^j)_r\,C(O)OR^{46}$,
10) $(CR^iR^j)_rR^{46}$,
11) $(CR^iR^j)_r\,S(O)_{0-2}R^{61}$,
12) $(CR^iR^j)_r\,S(O)_{0-2}N(R^{46}R^{47})$,
13) $OS(O)_{0-2}R^{61}$,
14) $N(R^{46})C(O)R^{47}$,
15) $N(R^{46})S(O)_xR^{61}$,
16) $(CR^iR^j)_rN(R^{46})R^{61}$,
17) $(CR^iR^j)_rN(R^{46})R^{61}OR^{47}$,
18) $(CR^iR^j)_rN(R^{46})(CR^kR^l)_sC(O)N(R^{47}R^{48})$,
19) $N(R^{46})(CR^iR^j)_rR^{61}$,
20) $N(R^{46})(CR^iR^j)_rN(R^{47}R^{48})$,
21) $(CR^iR^j)_rC(O)N(R^{47}R^{48})$, or
22) oxo, or

c) a 4-, 5- or 6-membered heterocyclic ring containing 1 or 2 nitrogen atoms, unsubstituted, mono-substituted or di-substituted with C_1-C_6 alkyl;

Y is CH_2, NR^{53}, $NC(O)R^{53}$, $S(O)_{0-2}$ or O;

G is H_2 or O;

R^a, R^b, R^c, R^d, R^e, R^f, R^g, R^h, R^i, R^j, R^k, and R^l are independently selected from the group consisting of:

1) hydrogen,
2) C_1-C_6 alkyl,
3) halogen,
4) aryl,
5) R^{80},
6) C_3-C_{10} cycloalkyl, and
7) OR^4,

said alkyl, aryl, and cycloalkyl being unsubstituted, monosubstituted with R^7, disubstituted with R^7 and R^{15}, trisubstituted with R^7, R^{15} and R^{16}, or tetrasubstituted with R^7, R^{15}, R^{16} and R^{17};

R^1 is independently selected from:

1) hydrogen,
2) halogen,
3) NO_2,
4) CN,
5) $CR^{40}=C(R^{41}R^{42})$,
6) $C\equiv CR^{40}$,
7) $(CR^aR^b)_nOR^{40}$,
8) $(CR^aR^b)_nN(R^{40}R^{41})$,
9) $(CR^aR^b)_nC(O)R^{40}$,
10) $(CR^aR^b)_nC(O)OR^{40}$,
11) $(CR^aR^b)_nR^{40}$,
12) $(CR^aR^b)_nS(O)_{0-2}R^6$,
13) $(CR^aR^b)_nS(O)_{0-2}N(R^{40}R^{41})$,
14) $OS(O)_{0-2}R^6$,
15) $N(R^{40})C(O)R^{41}$,
16) $N(R^{40})S(O)_{0-2}R^6$,
17) $(CR^aR^b)_nN(R^{40})R^6$,
18) $(CR^aR^b)_nN(R^{40})R^6OR^{41}$,
19) $(CR^aR^b)_nN(R^{40})(CR^cR^d)_tC(O)N(R^{41}R^{42})$,
20) $N(R^{40})(CR^aR^b)_nR^6$,
21) $N(R^{40})(CR^aR^b)_nN(R^{41}R^{42})$,

22)  ,

23)  ,

24)  ,

25) $(CR^aR^b)_nC(O)N(R^{41}R^{42})$, and

26) a 4-, 5-, or 6-membered heterocyclic ring containing 1 nitrogen atom, unsubstituted, or mono-, di- or tri-substituted with -OH;

R^2, R^8, R^9 and R^{10} are independently selected from:

1) hydrogen,
2) halogen,
3) NO_2,
4) CN,
5) $CR^{43}=C(R^{44}R^{45})$,
6) $C\equiv CR^{43}$,
7) $(CR^eR^f)_pOR^{43}$,
8) $(CR^eR^f)_pN(R^{43}R^{44})$,
9) $(CR^eR^f)_pC(O)R^{43}$,
10) $(CR^eR^f)_pC(O)OR^{43}$,
11) $(CR^eR^f)_pR^{43}$,
12) $(CR^eR^f)_pS(O)_{0-2}R^{60}$,
13) $(CR^eR^f)_pS(O)_{0-2}N(R^{43}R^{44})$,
14) $OS(O)_{0-2}R^{60}$,
15) $N(R^{43})C(O)R^{44}$,

16) $N(R^{43})S(O)_{0-2}R^{60}$,
17) $(CR^eR^f)_pN(R^{43})R^{60}$,
18) $(CR^eR^f)_pN(R^{43})R^{60}OR^{44}$,
19) $(CR^eR^f)_pN(R^{43})(CR^gR^h)_qC(O)N(R^{44}R^{45})$,
20) $N(R^{43})(CR^eR^f)_pR^{60}$,
21) $N(R^{43})(CR^eR^f)_pN(R^{44}R^{45})$, and
22) $(CR^eR^f)_pC(O)N(R^{43}R^{44})$,

or R^2 and R^8 are independently as defined above, and R^9 and R^{10}, together with the atoms to which they are attached, form the ring



, where R^m is C_{1-6}alkyl;

R^4, R^{40}, R^{41}, R^{42}, R^{43}, R^{44}, R^{45}, R^{46}, R^{47}, R^{48}, R^{49}, R^{50}, R^{51}, R^{52}, and R^{53} are independently selected from:

1) hydrogen,
2) C_1-C_6 alkyl,
3) C_3-C_{10} cycloalkyl,
4) aryl,
5) R^{81},
6) CF_3,
7) C_2-C_6 alkenyl, and
8) C_2-C_6 alkynyl,

said alkyl, aryl, and cycloalkyl is unsubstituted, mono-substituted with R^{18}, di-substituted with R^{18} and R^{19}, tri-substituted with R^{18}, R^{19} and R^{20}, or tetra-substituted with R^{18}, R^{19}, R^{20} and R^{21};

R^5 is independently selected from:

1) hydrogen,
2) halogen,
3) CN,
4) $C(O)N(R^{49}R^{50})$,
5) $C(O)OR^{49}$,
6) $S(O)_{0-2}N(R^{49}R^{50})$,
7) $S(O)_{0-2}R^{62}$,
8) C_1-C_6 alkyl,
9) C_3-C_{10} cycloalkyl,
10) R^{82},

said alkyl, aryl, and cycloalkyl is unsubstituted, mono-substituted with R^{22}, di-substituted with R^{22} and R^{23}, tri-substituted with R^{22}, R^{23} and R^{24}, or tetra-substituted with R^{22}, R^{23}, R^{24} and R^{25};

R^6, R^{60}, R^{61}, R^{62} and R^{63} are independently selected from:

1) C_1-C_6 alkyl,
2) aryl,
3) R^{83}, and
4) C_3-C_{10} cycloalkyl;

said alkyl, aryl, and cycloalkyl is unsubstituted, mono-substituted with R^{26}, di-substituted with R^{26} and R^{27}, tri-substituted with R^{26}, R^{27} and R^{28}, or tetra-substituted with R^{26}, R^{27}, R^{28} and R^{29};

R^7, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, R^{24}, R^{25}, R^{26}, R^{27}, R^{28}, R^{29}, and R^{70} are independently selected from:

1) C_1-C_6 alkyl,
2) halogen,
3) OR^{51},
4) CF_3,
5) aryl,
6) C_3-C_{10} cycloalkyl,
7) R^{84},
8) $S(O)_{0-2}N(R^{51}R^{52})$,
9) $C(O)OR^{51}$,
10) $C(O)R^{51}$,
11) CN,
12) $C(O)N(R^{51}R^{52})$,
13) $N(R^{51})C(O)R^{52}$,
14) $S(O)_{0-2}R^{63}$,
15) NO_2, and
16) $N(R^{51}R^{52})$;

R^{80}, R^{81}, R^{82}, R^{83} and R^{84} are independently selected from a group of unsubstituted or substituted heterocyclic rings consisting of a 4-6 membered unsaturated or saturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting N, O and S, and a 9- or 10-membered unsaturated or saturated bicyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting or N, O or S;

n, p, q, r, s and t are independently 0, 1, 2, 3, 4, 5 or 6;

u is 0, 1 or 2; and
v is 0, 1 or 2.

2. A compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein: A is a) an aryl ring selected from phenyl, unsubstituted or substituted as in Claim 1, b) a heteroaryl ring, unsubstituted or substituted as in Claim 1, selected from the group consisting of pyridine, pyrimidine, pyrazine, pyridazine, indole, pyrrolopyridine, benzimidazole, benzoxazole, benzothiazole, and benzoxadiazole, or c) a 4-, 5- or 6-membered heterocyclic ring as defined in Claim 1;
R^2, R^8, R^9 and R^{10} are independently selected from the group consisting of:

1) hydrogen,
2) halogen,
3) OR^{43}, and
4) $(CR^eR^f)_pR^{43}$,

or R^2 and R^8 are independently as defined above, and R^9 and R^{10}, together with the atoms to which they are attached, form the ring



, where R^m is C_{1-6}alkyl;

R^1 is independently selected from:

1) hydrogen,
2) halogen,
3) CN,
4) OR^{40},
5) $N(R^{40}R^{41})$,
6) $C(O)OR^{40}$,
7) R^{81},
8) $S(O)_{0-2}R^6$,
9) $N(R^{40})(CR^aR^b)_nR^6$, wherein $R^6 = R^{83}$,
10) $N(R^{40})(CR^aR^b)_nN(R^{41}R^{42})$,

11)



,

12)  ,

13) C(O)N($R^{41}R^{42}$), and

14) a 4-, 5-, or 6-membered heterocyclic ring containing 1 nitrogen atom, unsubstituted, or mono-, di- or tri-substituted with -OH.

3. A compound of Claim 2, or a pharmaceutically acceptable salt thereof, wherein R^2, R^8, and R^{10} are independently selected from hydrogen and halogen, and R^9 is OCH_3 or $OCHF_2$.

4. A compound of Claim 3, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from the group consisting of hydrogen, $-SCH_3$, $-SO_2CH_3$, $-NH(CH_2)_3OH$, $-NH(CH_2)_2OH$, $-NH(CH_2)_2OCH_3$,

$-NH(CH_2)_3OCH_3$, $-NH(CH_2)_2NH_2$, $-NH_2$, $-SO_2CH_2CH_3$, -CN, Cl, $-OCH_3$,

$-OCH_2CHCH_2$, $-OCH_2CH(OH)CH_2OH$, $-NHCH_2CHCH_2$, $-CH_3$, $-CH_2CH_2OH$,

$-O(CH_2)_2CHCH_2$, $-O(CH_2)_2CH(OH)(CH_2OH)$, $-NHCH(CH_2OH)_2$,

$-NHCH_2CH(OH)CH_2OH$, $-NH(CH_2)_2CH(OH)CH_2OH$,



5. A compound of Claim 4, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of

1) phenyl, wherein any stable ring atom is unsubstituted or substituted with halogen,

2) pyridinyl, wherein any stable C ring atom is unsubstituted or substituted with halogen,

3) indolyl, wherein any stable C or N ring atom is unsubstituted or substituted with halogen, and
4) a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, piperazine, and azetidine, unsubstituted, mono-substituted or di-substituted with C_1-C_6 alkyl.

6. A compound of Claim 5, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from the group consisting of CN and C_1-C_6 alkyl, wherein said alkyl is unsubstituted, mono-substituted with R^{22}, di-substituted with R^{22} and R^{23}, tri-substituted with R^{22}, R^{23} and R^{24}, or tetra-substituted with R^{22}, R^{23}, R^{24} and R^{25}.

7. A compound of Claim 6, or a pharmaceutically acceptable salt thereof, selected from the group consisting of
[(6-methoxy-4-phenylisoquinolin-3-yl)methyl]dimethylamine,
1-(1-chloro-6-methoxy-4-phenylisoquinolin-3-yl)-N,N-dimethylmethanamine,
{[6-methoxy-1-(methylthio)-4-phenylisoquinolin-3-yl]methyl}dimethylamine,
[6-methoxy-1-(methylsulfonyl)-4-phenylisoquinolin-3-yl]methyl(dimethyl)amine oxide,
1-[6-methoxy-1-(methylsulfonyl)-4-phenylisoquinolin-3-yl]-N,N-dimethylmethanamine,
3-[(dimethylamino)methyl]-6-methoxy-4-phenylisoquinoline-1-carbonitrile,
2,3-Dimethyl-6-methoxy-4-phenylisoquinolinium hydroxide,
6-methoxy-1-(2-methoxyethoxy)-3-methyl-4-phenylisoquinoline,
{3-[(6-methoxy-3-methyl-4-phenylisoquinolin-1-yl)oxy]propyl}amine,
2-[(6-methoxy-3-methyl-4-phenylisoquinolin-1-yl)amino]ethanol,
6-methoxy-3-methyl-1-(methylsulfonyl)-4-phenylisoquinoline,
6-methoxy-N-(2-methoxyethyl)-3-methyl-4-phenylisoquinolin-1-amine,
N-(6-methoxy-3-methyl-4-phenylisoquinolin-1-yl)ethane-1,2-diamine,
6-methoxy-3-methyl-4-phenylisoquinoline,
N-(3,4-dimethoxybenzyl)-6-methoxy-3-methyl-4-phenylisoquinolin-1-amine,
6-methoxy-3-methyl-4-phenylisoquinolin-1-amine,
1-(ethylsulfonyl)-6-methoxy-3-methyl-4-phenylisoquinoline,

1-(benzylsulfonyl)-6-methoxy-3-methyl-4-phenylisoquinoline,

6-methoxy-3-methyl-4-phenyl-1-(phenylsulfonyl)isoquinoline,

6-methoxy-3-methyl-4-phenylisoquinoline-1-carbonitrile,

3-tert-butyl-6-methoxy-1-(2-methoxyethoxy)-4-phenylisoquinoline,

1-chloro-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

6-methoxy-4-phenylisoquinoline-1,3-dicarbonitrile,

1-(allyloxy)-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-(2,3-dihydroxypropoxy)-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

(allylamino)-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

(+/-)-1-[(2,3-dihydroxypropyl)amino]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-{[(2S)-2,3-dihydroxypropyl]amino}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-{[(2R)-2,3-dihydroxypropyl]amino}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

(+/-)-1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-{[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-{[(2R)-2,3-dihydroxypropyl]oxy}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-{[(2S)-2,3-dihydroxypropyl]oxy}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

(+/-)-1-{[2,3-dihydroxypropyl]oxy}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-[(3R)-3-hydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-[(3S)-3-hydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

(+/-)-1-[3-hydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-[cis-3,4-dihydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

6-methoxy-4-phenyl-1-pyrrolidin-1-ylisoquinoline-3-carbonitrile,

6-methoxy-1-(methylsulfonyl)-4-phenylisoquinoline-3-carbonitrile,

6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1,6-dimethoxy-4-phenylisoquinoline-3-carbonitrile,

1-chloro-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

4-(3-fluorophenyl)-6-methoxy-1-methylisoquinoline-3-carbonitrile,

4-(3-fluorophenyl)-1-[(2-hydroxyethyl)amino]-6-methoxyisoquinoline-3-carbonitrile,

1-amino-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

4-(3-fluorophenyl)-1-[(3-hydroxypropyl)amino]-6-methoxyisoquinoline-3-carbonitrile,

1-(but-3-enyloxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

(+/-)-1-(2,3-dihydroxypropoxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(2R)-2,3-dihydroxypropoxy]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(2S)-2,3-dihydroxypropoxy]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

(+/-)-1-(3,4-dihydroxybutoxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

(+/-)-1-[(3R)-3,4-dihydroxybutoxy]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(3S)-3,4-dihydroxybutoxy]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

(+/-)-1-[(1,4-dioxan-2-ylmethyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(1,4-dioxan-(2R)-2-ylmethyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(1,4-dioxan-(2S)-2-ylmethyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

4-(3-fluorophenyl)-6-methoxy-1-[(1-methyl-1H-imidazol-4-yl)methoxy]isoquinoline-3-carbonitrile,

(+/-)-1-(1,3-dioxolan-4-ylmethoxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-(1,3-dioxolan-(4R)-4-ylmethoxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-(1,3-dioxolan-(4S)-4-ylmethoxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-(1,3-dioxan-5-yloxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

4-(3-fluorophenyl)-1-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-6-methoxyisoquinoline-3-carbonitrile,

4-(3-fluorophenyl)-1-(1H-imidazol-5-ylmethoxy)-6-methoxyisoquinoline-3-carbonitrile,

1-{[(2R)-2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-{[(2S)-2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

(+/-)-1-{[2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-(1H-imidazol-1-yl)-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

6-methoxy-4-phenyl-1-[(pyridin-2-ylmethyl)amino]isoquinoline-3-carbonitrile,

6-methoxy-4-phenyl-1-[(2-pyridin-2-ylethyl)amino]isoquinoline-3-carbonitrile,

(+/-)-1-[(3,4-dihydroxybutyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(3R)-(3,4-dihydroxybutyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(3S)-(3,4-dihydroxybutyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-chloro-4-(2-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

4-(2-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

(+/-)-1-[(2,3-dihydroxypropyl)amino]-4-(2-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(2S)-(2,3-dihydroxypropyl)amino]-4-(2-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(2R)-(2,3-dihydroxypropyl)amino]-4-(2-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

(+/-)-6-(difluoromethoxy)-1-{[2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

6-(difluoromethoxy)-1-{[(2S)-2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

6-(difluoromethoxy)-1-{[(2R)-2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

(+/-)-6-(difluoromethoxy)-1-{[2,3-dihydroxypropyl]oxy}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

6-(difluoromethoxy)-1-{[(2S)-2,3-dihydroxypropyl]oxy}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

6-(difluoromethoxy)-1-{[(2R)-2,3-dihydroxypropyl]oxy}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

1-(4-hydroxypiperidin-1-yl)-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-azetidin-1-yl-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

(+/-)-1-[trans-3,4-dihydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-[(3R,4R)-3,4-dihydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile, and

6-methoxy-N-(3-methoxypropyl)-3-methyl-4-phenylisoquinolin-1-amine.

8. A method of treating a condition in a mammal, the treatment of which is effected or facilitated by $K_V1.5$ inhibition, which comprises administering a compound of Claim 1 in an amount that is effective at inhibiting $K_V1.5$.

9. A method of Claim 8, wherein the condition is cardiac arrythmia.

10. A method of Claim 9, wherein the cardiac arrythmia is atrial fibrillation.

11. A method of Claim 9, wherein the cardiac arrythmia is selected from the group consisting of atrial flutter, atrial arrhythmia and supraventricular tachycardia.

12. A method of preventing a condition in a mammal, the prevention of which is effected or facilitated by $K_V1.5$ inhibition, which comprises administering a compound of Claim 1 in an amount that is effective at inhibiting $K_V1.5$.

13. A method of Claim 12, wherein the condition is cardiac arrythmia.

14. A method of Claim 13, wherein the cardiac arrythmia is atrial fibrillation.

15. A method of Claim 13, wherein the cardiac arrythmia is selected from the group consisting of atrial flutter, atrial arrhythmia and supraventricular tachycardia.

16. A method of Claim12, wherein the condition is a thromboembolic event.

17. A method of Claim 16, wherein the thromboembolic event is a stroke.

18. A method of Claim 12, wherein the condition is congestive heart failure.

19. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and the compound Claim 1 or a pharmaceutically acceptable crystal form or hydrate thereof.

20. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

21. A method of treating cardiac arrythmia comprising administering a compound of Claim 1 with a compound selected from one of the classes of compounds consisting of antiarrhythmic agents having Kv1.5 blocking activities, ACE inhibitors, angiotensin II antagonists, cardiac glycosides, L-type calcium channel blockers, T-type calcium channel blockers, selective and nonselective beta blockers, endothelin antagonists, thrombin inhibitors, aspirin, nonselective NSAIDs, warfarin, factor Xa inhibitors, low molecular weight heparin, unfractionated heparin, clopidogrel, ticlopidine, IIb/IIIa receptor antagonists, 5HT receptor antagonists, integrin receptor antagonists, thromboxane receptor antagonists, TAFI inhibitors and P2T receptor antagonists.

22. A method for inducing a condition of normal sinus rhythm in a patient having atrial fibrillation, which comprises treating the patient with a compound of Claim 1.

23. A method for treating tachycardia in a patient which comprises treating the patient with an antitachycardia device in combination with a compound of Claim 1.